# ASP Isotopes has entered into a strategic partnership with Isotopia Molecular Imaging to supply Gadolinium-160, vital for producing an emerging cancer-fighting isotope called terbium-161. ASP will use its quantum technology to meet growing medical demand. The deal targets prostate cancer, neuroendocrine tumors and other malignancies, removing key supply bottlenecks. ASP CEO Paul Mann says this partnership accelerates the path to clinical adoption of Tb-161, which could redefine cancer treatment paradigms. ASP also plans a Johannesburg Stock Exchange listing later this year to broaden its investor base.
ASP Isotopes signs deal to boost cancer treatment